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The results differ significantly, which partly may be explained through the study design. Inclusion criteria, conditioning regimens and feasibility of the procedures were different. The French trial focused on patients with high-risk disease, defined by both elevated b2-microglobuline and chromosome 13 deletion at diagnosis, 8 whereas the Italian group included all patients irrespective of the prognostic factors. The Spanish group restricted the genetic randomization to chemosensitive patients failing to achieve CR or near-CR following a first auto-SCT. All patients received a first auto-SCT prepared by melphalan 200 mg/m 2 (mel 200) in the French trial, whereas the doses of melphalan varied from 100 to 200 mg/m 2 in the Italian trial, and the Spanish group used either mel 200 or 12 Gy TBI plus mel 140. Moreover, in the latter trial, the second auto-SCT was prepared either by mel 200 or CVB. In the allogeneic arm, high-dose ATG was used in the French trial, low-dose TBI only in the Italian study, and a more dose-intensive regimen, combining mel 140 with fludarabin, was infused in the Spanish group. The tandem auto-SCT was completed in 56% of the patients in the Italian trial as compared with 76% in the French trial, whereas the feasibility of the planned auto-SCT/RIC-allo was identical in these two trials (72 and 71%, respectively).
Toxicity is identical in the three studies. The TRM rate of the second auto-SCT ranged from 2 to 5%, whereas the mortality of the RIC-allo-SCT ranged from 10 to 16%, confirming the lower toxicity of tandem auto-SCT.
Response rates after completion of therapy are difficult to compare. As mentioned earlier, the Spanish study enrolled chemosensitive patients after a first auto-SCT only, indicating that all patients were at least in partial response at the time of second auto-SCT or RIC-allo-SCT.
The overall response rate was identical for the French and the Italian trials, with partial response rate 480% in both arms of the two studies in patients who completed the whole program.
The follow-up of the three trials is long enough to draw conclusions regarding overall survival and EFS. In the French trial, on an intent-to-treat basis, the EFS did not significantly differ from tandem auto-SCT to single autograft followed by allo-RIC. Nevertheless, there was a trend for a superior overall survival in the double auto-SCT arm, where patients more often were able to receive salvage therapies. Unfortunately, no plateau was observed on survival curves in both arms of the trial. The results of the Italian trial are exactly the opposite. Both EFS and overall survival were in favor of the auto-SCT/RIC-allo arm for patients who completed the whole protocol, but also on an intent-to-treat basis, with a true plateau on the survival curves of the auto-SCT/RIC-allo arm. In the Spanish trial, there was a trend toward a longer PFS in favour of allo-RIC, but both EFS and overall survival were not significantly different between second auto-SCT and allo-RIC.
These results highlight the impact of inclusion criteria (high-risk patients or not), conditioning regimens before RIC allotransplant (high-dose ATG in the French trial that may have inhibited donor cytotoxic cells responsible for the graft-vs-myeloma effect leading to a high relapse rate, vs 2 Gy TBI in the Italian trial that does not preclude the graft-vs-myeloma effect, or use of cytotoxic drugs such as melphalan in the Spanish group) or before double auto-SCT (optimized dose-intensity mel 200 þ mel 220 in the French trial) on outcome in such trials.
To better define the role of these strategies in de novo multiple myeloma patients, we eagerly await the results of four additional recently completed prospective phase III trials in North America (BMT-CTN 01-02) and Europe (EBMT NMAM2000, Hovon, GMMSG) that have compared double auto-SCT with single auto-SCT followed by non-myeloablative allo-SCT.
